During the initial phase of testosterone therapy, blood work is checked at 6 to 12 weeks to calibrate dosage and verify safety. Once a steady therapeutic state is established and clinical symptoms improve, the frequency of testing decreases.
Established clinical guidelines recommend periodic monitoring every 6 to 12 months for men on stable, long-term TRT.
These regular follow-up panels assess total and free testosterone, hematocrit, PSA, liver and kidney function, and lipid profiles to ensure ongoing therapeutic safety and efficacy.
Risks and limitations
- More frequent testing may be required if your dosage changes, if new clinical symptoms develop, or if safety markers such as hematocrit or PSA show upward trends.
- Skipping recommended routine monitoring can lead to undetected polycythemia or unmonitored prostate changes.